Emcure Pharmaceuticals shares gained 2.99% to ₹1,836.50 on Monday following Motilal Oswal's initiation of coverage with a Buy rating and target price of ₹2,260, implying a potential upside of 23% from current market levels. According to the brokerage's analysis, the recommendation is based on the company's strong fundamentals and growth prospects across multiple international markets.
Motilal Oswal has significantly upgraded its financial projections for Emcure Pharmaceuticals, with the brokerage now expecting 14% revenue CAGR over FY26-28 across key segments. For the Canada business, the brokerage projects 14% sales CAGR over FY26-28, taking revenue to ₹19.4 billion, while the rest-of-world business is expected to reach ₹26 billion at an 18% CAGR over the same period. The domestic business is anticipated to achieve 11% sales CAGR to reach ₹49 billion in revenue over FY26-28, driven by new launches and improving traction in base products. The brokerage estimates robust 14% revenue growth, 20% EBITDA, and 28% PAT growth annually over FY26-28 on a compounded basis, driven by a differentiated product pipeline and efficient commercial channel network.
The brokerage highlighted Emcure's strong international performance, noting that over FY23-26, international revenue delivered CAGR of 21% YoY. The Europe business delivered a 16% CAGR over FY23-26, while the Canada segment demonstrated exceptional growth with a 26.8% CAGR during the same period. Motilal Oswal expects this multimarket engine to sustain a 16-18% CAGR across EU, Canada and ROW over FY26-28. Emcure has built a significant global presence, particularly in Canada and Europe, which, together with other markets, contributed almost 56% of FY26 revenue. Canada has emerged as the company's fastest-growing and most profitable international market, while the European segment has outperformed the market by nearly 500 basis points in revenue growth between FY23 and FY26.
Motilal Oswal highlighted Emcure's aggressive expansion strategy through M&A-led value enhancement, with the company spending an aggregate of ₹10 billion to enhance its value chain through inorganic routes. The brokerage noted that Emcure has built a dedicated dermatology platform, entered adjacent consumer wellness categories, and is developing a super-specialty platform focused on ophthalmology and oncology. The company maintains a strong, diversified domestic franchise anchored by leadership in women's health (ranking 2nd in gynaecology) and is actively expanding into other chronic areas, including cardiology, CNS, anti-diabetes, and oncology, supported by increased field-force coverage and brand-building efforts. Emcure leverages high-ROCE, asset-light partnerships with global innovators, including Sanofi for cardiovascular treatments, Novo Nordisk for diabetes and obesity (specifically semaglutide), and Roche for nephrology and transplant portfolios.
Emcure Pharma delivered strong Q4FY26 results with net profit rising 29% year-on-year to ₹243 crore from ₹189 crore in Q4FY25, while revenue surged 17% YoY to ₹2,469.7 crore compared to ₹2,116.2 crore in the corresponding period. On the operating front, EBITDA increased 19% YoY to ₹479.5 crore in Q4FY26, with margins improving marginally to 19.4% from 19% a year earlier. The company's diversified earnings base with a 20% average RoE over FY26-28 led Motilal Oswal to assign an industry-level PE multiple of 28x to Emcure Pharma. This valuation is supported by the company's ability to sustain a healthy Return on Equity of almost 20%, a metric achieved by only seven companies within Motilal Oswal's 29-company healthcare coverage universe. The stock has delivered 35.5% returns over the previous 12 months and 20% returns in the last six months, with recent gains of 9% in the last five trading sessions.
